PUBLICATION
Etamycin as a Novel Mycobacterium abscessus Inhibitor
- Authors
- Hanh, B.T.B., Kim, T.H., Park, J.W., Lee, D.G., Kim, J.S., Du, Y.E., Yang, C.S., Oh, D.C., Jang, J.
- ID
- ZDB-PUB-201002-140
- Date
- 2020
- Source
- International Journal of Molecular Sciences 21(18): (Journal)
- Registered Authors
- Keywords
- Mycobacterium abscessus, drug resistance, novel drug discovery
- MeSH Terms
-
- Animals
- Female
- Fish Diseases*/drug therapy
- Fish Diseases*/microbiology
- Macrolides/pharmacology*
- Mice
- Mycobacterium Infections, Nontuberculous/drug therapy*
- Mycobacterium abscessus/growth & development*
- Zebrafish/microbiology*
- PubMed
- 32967077 Full text @ Int. J. Mol. Sci.
Citation
Hanh, B.T.B., Kim, T.H., Park, J.W., Lee, D.G., Kim, J.S., Du, Y.E., Yang, C.S., Oh, D.C., Jang, J. (2020) Etamycin as a Novel Mycobacterium abscessus Inhibitor. International Journal of Molecular Sciences. 21(18):.
Abstract
The increase in drug-resistant Mycobacterium abscessus, which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against M. abscessus. We found that etamycin significantly inhibited the growth of M. abscessus wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of M. abscessus that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish (Danio rerio) infection model was greater than that of clarithromycin, which is recommended as the core agent for treating M. abscessus infections. Thus, we concluded that etamycin is a potential anti-M. abscessus candidate for further development as a clinical drug candidate.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping